Medpace, Fortrea Cut as Jefferies Reviews CROs Amid Biotech Headwinds
Here's How Much $100 Invested In Icon 10 Years Ago Would Be Worth Today
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $340
Express News | Baird Maintains Outperform on Icon, Lowers Price Target to $340
Express News | ICON PLC : Baird Cuts Target Price to $340 From $368
ICON Draws Bullish View at Leerink on Business Model
Icon Initiated at Outperform by Leerink Partners
Icon Price Target Announced at $379.00/Share by Leerink Partners
Leerink Partners Initiates Icon PLC(ICLR.US) With Buy Rating, Announces Target Price $379
Express News | ICON PLC : Leerink Partners Initiates Coverage With Outperform Rating; Target Price $379
Implied Volatility Surging for ICON (ICLR) Stock Options
Here's Why ICON (NASDAQ:ICLR) Can Manage Its Debt Responsibly
ICON Survey Highlights Scale of Focus on Precision Therapies in Increasingly Complex Oncology Landscape
Icon PLC (ICLR) Surges 3.3%: Is This an Indication of Further Gains?
ICON Shares Rebound as Analysts Say Selloff Is Overdone
Icon Price Target Maintained With a $368.00/Share by Baird
Icon Is Maintained at Outperform by Baird
Express News | Truist Securities Reiterates Buy on Icon, Maintains $383 Price Target
Icon Analyst Ratings
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $368